Health Care
Washington, D.C. – Today, Congressman Frank Pallone, Jr. (NJ-06), top Democrat on the House Energy and Commerce Committee, announced that his Cardiomyopathy Health, Education, Awareness, Research, and Training in Schools (HEARTS) Act has overwhelmingly passed the U.S. House of Representatives.
Washington, D.C. – Tonight, Congressman Frank Pallone, Jr. (D-NJ) led a bipartisan effort to honor the memory of his late colleague and close friend, Congressman Bill Pascrell, Jr. (D-NJ), by preserving Pascrell's groundbreaking work on traumatic brain injury (TBI) awareness and treatment.
Piscataway, NJ – Congressman Frank Pallone, Jr. (NJ-06), ranking member of the House Energy and Commerce Committee, held a press conference at the Piscataway Senior Citizen Center to discuss new Medicare drug price negotiations—a key provision of the Inflation Reduction Act.
As Medicare negotiates lower prices, we are slashing drug costs for New Jersey residents
Frank Pallone Jr.
Special to the USA TODAY Network
LONG BRANCH, NJ – Congressman Frank Pallone, Jr. (D-N.J.) is highlighting legislation in his House Energy and Commerce Committee – H.R.
Washington, D.C. – Congressman Frank Pallone, Jr. (D-NJ), the top Democrat on the House Energy & Commerce Committee, today praised the Biden-Harris Administration’s successful negotiation of Medicare prescription drug prices for the first time in the program's history—a direct result of the Inflation Reduction Act.
New Brunswick, NJ – Congressman Frank Pallone, Jr. (NJ-06), Ranking Member of the House Energy and Commerce Committee, today led a roundtable discussion at Rutgers Robert Wood Johnson Medical School to highlight the alarming findings of a new report released by his committee.
Long Branch, NJ – Congressman Frank Pallone (NJ-06), top Democrat on the House Energy and Commerce Committee, today visited the Monmouth Family Health Center as part of National Health Center Week (August 4-10).
LONG BRANCH, NJ – Congressman Frank Pallone, Jr. (NJ-06) today expressed strong support for the U.S. Pharmacopeia's (USP) new guidelines for the use of synthetic alternatives to horseshoe crab blood in drug and medical device safety testing.